Skip to main content
Premium Trial:

Request an Annual Quote

Question Time

The Reddit commentariat is a tough crowd — even, it turns out, for a Nobel laureate.

Randy Schekman, who shared this year's Nobel Prize in Physiology or Medicine for his work on cell transport, took to the website yesterday for an "Ask Me Anything" session, subjecting himself to slings and arrows of the Reddit crowd.

Much of the discussion revolved around Schekman's recent announcement that his lab would no longer be publishing in "luxury" journals like Science, Nature, and Cell. As more than one commenter pointed out — and as Schekman himself admitted — this isn't an especially bold stand for someone who just won the Nobel.

A number of commenters also noted that Schekman's anti-luxury journal stance is perhaps not entirely disinterested given his role as editor of the open-access journal eLife.

"I think it's also slightly self-serving for you to try to spearhead a movement away from big name journals, when you are the editor of a new journal," one says.

And then, of course, there was wordplay:

"You were the editor of PNAS? How many jokes were made involving the name?"

Keep it classy, Redditors.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.